Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Nvidia Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Nvidia Corp trades at $210.95 (market cap $4.93T). The key difference: Nvidia Corp is far larger — about 614.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Nvidia Corp pays a 0.49% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | NVDA | |
|---|---|---|
Market Cap | $8.02B | $4.93T |
Sector | Health | Technology |
52-Week High | $339.75 | $235.75 |
52-Week Low | $241.71 | $165.17 |
Enterprise Value | $7.84B | $4.86T |
Dividend Yield | — | 0.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
NVIDIA (NVDA) trades at $203.53, down 3.52% on the day, with a bullish technical outlook supported by moving averages and key support at $201. The company reported strong revenue growth to $130.50B in 2025, with net income surging to $72.88B and a robust net margin of 55.84%. Recent earnings beats and a consensus analyst price target of $325.86 highlight strong fundamental momentum amid AI-driven demand.
Outlook remains positive with AI infrastructure expansion driving growth, though risks include increased competition and market volatility. Wall Street sentiment is bullish with 75% buy ratings, but investors should monitor execution risks and macroeconomic headwinds that could impact valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
